HPTN 071 (PopART): rationale and design of a cluster-randomised trial of the population impact of an HIV combination prevention intervention including universal testing and treatment - a study protocol for a cluster randomised trial

Richard Hayes, Helen Ayles, Nulda Beyers, Kalpana Sabapathy, Sian Floyd, Kwame Shanaube, Peter Bock, Sam Griffith, Ayana Moore, Deborah Watson-Jones, Christophe Fraser, Sten H Vermund, Sarah Fidler, HPTN 071 (PopART) Study Team, Richard Hayes, Helen Ayles, Nulda Beyers, Kalpana Sabapathy, Sian Floyd, Kwame Shanaube, Peter Bock, Sam Griffith, Ayana Moore, Deborah Watson-Jones, Christophe Fraser, Sten H Vermund, Sarah Fidler, HPTN 071 (PopART) Study Team

Abstract

Background: Effective interventions to reduce HIV incidence in sub-Saharan Africa are urgently needed. Mathematical modelling and the HIV Prevention Trials Network (HPTN) 052 trial results suggest that universal HIV testing combined with immediate antiretroviral treatment (ART) should substantially reduce incidence and may eliminate HIV as a public health problem. We describe the rationale and design of a trial to evaluate this hypothesis.

Methods/design: A rigorously-designed trial of universal testing and treatment (UTT) interventions is needed because: i) it is unknown whether these interventions can be delivered to scale with adequate uptake; ii) there are many uncertainties in the models such that the population-level impact of these interventions is unknown; and ii) there are potential adverse effects including sexual risk disinhibition, HIV-related stigma, over-burdening of health systems, poor adherence, toxicity, and drug resistance.In the HPTN 071 (PopART) trial, 21 communities in Zambia and South Africa (total population 1.2 m) will be randomly allocated to three arms. Arm A will receive the full PopART combination HIV prevention package including annual home-based HIV testing, promotion of medical male circumcision for HIV-negative men, and offer of immediate ART for those testing HIV-positive; Arm B will receive the full package except that ART initiation will follow current national guidelines; Arm C will receive standard of care. A Population Cohort of 2,500 adults will be randomly selected in each community and followed for 3 years to measure the primary outcome of HIV incidence. Based on model projections, the trial will be well-powered to detect predicted effects on HIV incidence and secondary outcomes.

Discussion: Trial results, combined with modelling and cost data, will provide short-term and long-term estimates of cost-effectiveness of UTT interventions. Importantly, the three-arm design will enable assessment of how much could be achieved by optimal delivery of current policies and the costs and benefits of extending this to UTT.

Trial registration: ClinicalTrials.gov NCT01900977.

Figures

Figure 1
Figure 1
Summary of trial design.
Figure 2
Figure 2
Map showing location of study communities.

References

    1. UNAIDS. Global Report: UNAIDS Report on the Global AIDS Epidemic. 2012. [ ] Accessed 30 October 2013.
    1. Hankins CA, de Zalduondo BO. Combination prevention: a deeper understanding of effective HIV prevention. AIDS. 2010;24(Suppl 4):S70–S80. doi: 10.1097/01.aids.0000390709.04255.fd.
    1. Pirrone V, Thakkar N, Jacobson JM, Wigdahl B, Krebs FC. Combinatorial approaches to the prevention and treatment of HIV-1 infection. Antimicrob Agents Chemother. 2011;55(5):1831–1842. doi: 10.1128/AAC.00976-10.
    1. Templeton DJ. Male circumcision to reduce sexual transmission of HIV. Curr Opin HIV AIDS. 2010;5(4):344–349. doi: 10.1097/COH.0b013e32833a46d3.
    1. Auvert B, Taljaard D, Lagarde E, Sobngwi-Tambekou J, Sitta R, Puren A. Randomized, controlled intervention trial of male circumcision for reduction of HIV infection risk: the ANRS 1265 Trial. PLoS Med. 2005;2(11):e298. doi: 10.1371/journal.pmed.0020298.
    1. Bailey RC, Moses S, Parker CB, Agot K, Maclean I, Krieger JN, Williams CF, Campbell RT, Ndinya-Achola JO. Male circumcision for HIV prevention in young men in Kisumu, Kenya: a randomised controlled trial. Lancet. 2007;369(9562):643–656. doi: 10.1016/S0140-6736(07)60312-2.
    1. Gray RH, Kigozi G, Serwadda D, Makumbi F, Watya S, Nalugoda F, Kiwanuka N, Moulton LH, Chaudhary MA, Chen MZ, Sewankambo NK, Wabwire-Mangen F, Bacon MC, Williams CF, Opendi P, Reynolds SJ, Laeyendecker O, Quinn TC, Wawer MJ. Male circumcision for HIV prevention in men in Rakai, Uganda: a randomised trial. Lancet. 2007;369(9562):657–666. doi: 10.1016/S0140-6736(07)60313-4.
    1. Johri M, Ako-Arrey D. The cost-effectiveness of preventing mother-to-child transmission of HIV in low- and middle-income countries: systematic review. Cost Eff Resour Alloc. 2011;9:3. doi: 10.1186/1478-7547-9-3.
    1. Volmink J, Siegfried NL, van der Merwe L, Brocklehurst P. Antiretrovirals for reducing the risk of mother-to-child transmission of HIV infection. Cochrane Database Syst Rev. 2007;1:CD003510.
    1. Chasela CS, Hudgens MG, Jamieson DJ, Kayira D, Hosseinipour MC, Kourtis AP, Martinson F, Tegha G, Knight RJ, Ahmed YI, Kamwendo DD, Hoffman IF, Ellington SR, Kacheche Z, Soko A, Wiener JB, Fiscus SA, Kazembe P, Mofolo IA, Chigwenembe M, Sichali DS, van der Horst CM. Maternal or infant antiretroviral drugs to reduce HIV-1 transmission. N Engl J Med. 2010;362(24):2271–2281. doi: 10.1056/NEJMoa0911486.
    1. de Vincenzi I. Triple antiretroviral compared with zidovudine and single-dose nevirapine prophylaxis during pregnancy and breastfeeding for prevention of mother-to-child transmission of HIV-1 (Kesho Bora study): a randomised controlled trial. Lancet Infect Dis. 2011;11(3):171–180.
    1. Shapiro RL, Hughes MD, Ogwu A, Kitch D, Lockman S, Moffat C, Makhema J, Moyo S, Thior I, McIntosh K, van Widenfelt E, Leidner J, Powis K, Asmelash A, Tumbare E, Zwerski S, Sharma U, Handelsman E, Mburu K, Jayeoba O, Moko E, Souda S, Lubega E, Akhtar M, Wester C, Tuomola R, Snowden W, Martinez-Tristani M, Mazhani L, Essex M. Antiretroviral regimens in pregnancy and breast-feeding in Botswana. N Engl J Med. 2010;362(24):2282–2294. doi: 10.1056/NEJMoa0907736.
    1. Buchbinder SP, Liu A. Pre-exposure prophylaxis and the promise of combination prevention approaches. AIDS Behav. 2011;15(Suppl 1):S72–S79.
    1. Granich R, Crowley S, Vitoria M, Smyth C, Kahn JG, Bennett R, Lo YR, Souteyrand Y, Williams B. Highly active antiretroviral treatment as prevention of HIV transmission: review of scientific evidence and update. Curr Opin HIV AIDS. 2010;5(4):298–304. doi: 10.1097/COH.0b013e32833a6c32.
    1. Cohen MS, Chen YQ, McCauley M, Gamble T, Hosseinipour MC, Kumarasamy N, Hakim JG, Kumwenda J, Grinsztejn B, Pilotto JH, Godbole SV, Mehendale S, Chariyalertsak S, Santos BR, Mayer KH, Hoffman IF, Eshleman SH, Piwowar-Manning E, Wang L, Makhema J, Mills LA, de Bruyn G, Sanne I, Eron J, Gallant J, Havlir D, Swindells S, Ribaudo H, Elharrar V, Burns D. et al.Prevention of HIV-1 infection with early antiretroviral therapy. N Engl J Med. 2011;365(6):493–505. doi: 10.1056/NEJMoa1105243.
    1. Hayes R, Sabapathy K, Fidler S. Universal testing and treatment as an HIV prevention strategy: research questions and methods. Curr HIV Res. 2011;9(6):429–445. doi: 10.2174/157016211798038515.
    1. Dodd PJ, Garnett GP, Hallett TB. Examining the promise of HIV elimination by ‘test and treat’ in hyperendemic settings. AIDS. 2010;24(5):729–735. doi: 10.1097/QAD.0b013e32833433fe.
    1. Granich RM, Gilks CF, Dye C, De Cock KM, Williams BG. Universal voluntary HIV testing with immediate antiretroviral therapy as a strategy for elimination of HIV transmission: a mathematical model. Lancet. 2009;373(9657):48–57. doi: 10.1016/S0140-6736(08)61697-9.
    1. Lima VD, Johnston K, Hogg RS, Levy AR, Harrigan PR, Anema A, Montaner JS. Expanded access to highly active antiretroviral therapy: a potentially powerful strategy to curb the growth of the HIV epidemic. J Infect Dis. 2008;198(1):59–67. doi: 10.1086/588673.
    1. Velasco-Hernandez JX, Gershengorn HB, Blower SM. Could widespread use of combination antiretroviral therapy eradicate HIV epidemics? Lancet Infect Dis. 2002;2(8):487–493. doi: 10.1016/S1473-3099(02)00346-8.
    1. Baggaley RF, Garnett GP, Ferguson NM. Modelling the impact of antiretroviral use in resource-poor settings. PLoS Med. 2006;3(4):e124. doi: 10.1371/journal.pmed.0030124.
    1. Eaton JW, Johnson LF, Salomon JA, Barnighausen T, Bendavid E, Bershteyn A, Bloom DE, Cambiano V, Fraser C, Hontelez JA, Humair S, Klein DJ, Long EF, Phillips AN, Pretorius C, Stover J, Wenger EA, Williams BG, Hallett TB. HIV treatment as prevention: systematic comparison of mathematical models of the potential impact of antiretroviral therapy on HIV incidence in South Africa. PLoS Med. 2012;9(7):e1001245. doi: 10.1371/journal.pmed.1001245.
    1. Garnett GP, Baggaley RF. Treating our way out of the HIV pandemic: could we, would we, should we? Lancet. 2009;373(9657):9–11. doi: 10.1016/S0140-6736(08)61698-0.
    1. Wagner BG, Kahn JS, Blower S. Should we try to eliminate HIV epidemics by using a ‘Test and Treat’ strategy? AIDS. 2010;24(5):775–776. doi: 10.1097/QAD.0b013e3283366782.
    1. Attia S, Egger M, Muller M, Zwahlen M, Low N. Sexual transmission of HIV according to viral load and antiretroviral therapy: systematic review and meta-analysis. AIDS. 2009;23(11):1397–1404. doi: 10.1097/QAD.0b013e32832b7dca.
    1. Wawer MJ, Gray RH, Sewankambo NK, Serwadda D, Li X, Laeyendecker O, Kiwanuka N, Kigozi G, Kiddugavu M, Lutalo T, Nalugoda F, Wabwire-Mangen F, Meehan MP, Quinn TC. Rates of HIV-1 transmission per coital act, by stage of HIV-1 infection, in Rakai. Uganda. J Infect Dis. 2005;191(9):1403–1409. doi: 10.1086/429411.
    1. Cohen MS, Gay C, Kashuba AD, Blower S, Paxton L. Narrative review: antiretroviral therapy to prevent the sexual transmission of HIV-1. Ann Intern Med. 2007;146(8):591–601. doi: 10.7326/0003-4819-146-8-200704170-00010.
    1. Gay CL, Cohen MS. Antiretrovirals to prevent HIV infection: pre- and postexposure prophylaxis. Curr Infect Dis Rep. 2008;10(4):323–331. doi: 10.1007/s11908-008-0052-5.
    1. Cu-Uvin S, DeLong AK, Venkatesh KK, Hogan JW, Ingersoll J, Kurpewski J, De Pasquale MP, D’Aquila R, Caliendo AM. Genital tract HIV-1 RNA shedding among women with below detectable plasma viral load. AIDS. 2010;24(16):2489–2497. doi: 10.1097/QAD.0b013e32833e5043.
    1. Clinical No NCT00867048. Strategic Timing of Antiretroviral Treatment (START) .
    1. De Cock KM, El-Sadr WM. When to start ART in Africa–an urgent research priority. N Engl J Med. 2013;368(10):886–889. doi: 10.1056/NEJMp1300458.
    1. Tanser F, Barnighausen T, Grapsa E, Zaidi J, Newell ML. High coverage of ART associated with decline in risk of HIV acquisition in rural KwaZulu-Natal. South Africa. Science. 2013;339(6122):966–971.
    1. Fox MP, Rosen S. Patient retention in antiretroviral therapy programs up to three years on treatment in sub-Saharan Africa, 2007–2009: systematic review. Trop Med Int Health. 2010;15(Suppl 1):1–15.
    1. Sabapathy K, Van den Bergh R, Fidler S, Hayes R, Ford N. Uptake of home-based voluntary HIV testing in sub-Saharan Africa: a systematic review and meta-analysis. PLoS Med. 2012;9(12):e1001351. doi: 10.1371/journal.pmed.1001351.
    1. MacPherson P, Lalloo DG, Choko AT, Mann GH, Squire SB, Mwale D, Manda E, Makombe SD, Desmond N, Heyderman R, Corbett EL. Suboptimal patterns of provider initiated HIV testing and counselling, antiretroviral therapy eligibility assessment and referral in primary health clinic attendees in Blantyre. Malawi. Trop Med Int Health. 2012;17(4):507–517. doi: 10.1111/j.1365-3156.2011.02946.x.
    1. Bello G, Simwaka B, Ndhlovu T, Salaniponi F, Hallett TB. Evidence for changes in behaviour leading to reductions in HIV prevalence in urban Malawi. Sex Transm Infect. 2011;87(4):296–300. doi: 10.1136/sti.2010.043786.
    1. Cremin I, Nyamukapa C, Sherr L, Hallett TB, Chawira G, Cauchemez S, Lopman B, Garnett GP, Gregson S. Patterns of self-reported behaviour change associated with receiving voluntary counselling and testing in a longitudinal study from Manicaland, Zimbabwe. AIDS Behav. 2010;14(3):708–715. doi: 10.1007/s10461-009-9592-4.
    1. Ross DA. Behavioural interventions to reduce HIV risk: what works? AIDS. 2010;24(Suppl 4):S4–S14. doi: 10.1097/01.aids.0000390703.35642.89.
    1. Coates TJ, Richter L, Caceres C. Behavioural strategies to reduce HIV transmission: how to make them work better. Lancet. 2008;372(9639):669–684. doi: 10.1016/S0140-6736(08)60886-7.
    1. Corbett EL, Makamure B, Cheung YB, Dauya E, Matambo R, Bandason T, Munyati SS, Mason PR, Butterworth AE, Hayes RJ. HIV incidence during a cluster-randomized trial of two strategies providing voluntary counselling and testing at the workplace, Zimbabwe. AIDS. 2007;21(4):483–489. doi: 10.1097/QAD.0b013e3280115402.
    1. Turner AN, Miller WC, Padian NS, Kaufman JS, Behets FM, Chipato T, Mmiro FA, Salata RA, Morrison CS. Unprotected sex following HIV testing among women in Uganda and Zimbabwe: short- and long-term comparisons with pre-test behaviour. Int J Epidemiol. 2009;38(4):997–1007. doi: 10.1093/ije/dyp171.
    1. NIMH Project Accept (HPTN 043) A Phase III Randomized Controlled Trial of Community Mobilization, Mobile Testing, Same-Day Results, and Post-Test Support for HIV in Sub-Saharan Africa and Thailand. .
    1. Hallett TB, Singh K, Smith JA, White RG, Abu-Raddad LJ, Garnett GP. Understanding the impact of male circumcision interventions on the spread of HIV in southern Africa. PLoS One. 2008;3(5):e2212. doi: 10.1371/journal.pone.0002212.
    1. Lissouba P, Taljaard D, Rech D, Doyle S, Shabangu D, Nhlapo C, Otchere-Darko J, Mashigo T, Matson C, Lewis D, Billy S, Auvert B. A model for the roll-out of comprehensive adult male circumcision services in African low-income settings of high HIV incidence: the ANRS 12126 Bophelo Pele Project. PLoS Med. 2010;7(7):e1000309. doi: 10.1371/journal.pmed.1000309.
    1. Ward H, Ronn M. Contribution of sexually transmitted infections to the sexual transmission of HIV. Curr Opin HIV AIDS. 2010;5(4):305–310. doi: 10.1097/COH.0b013e32833a8844.
    1. Grosskurth H, Mosha F, Todd J, Mwijarubi E, Klokke A, Senkoro K, Mayaud P, Changalucha J, Nicoll A, Ka-Gina G, Mugeye K. Impact of improved treatment of sexually transmitted diseases on HIV infection in rural Tanzania: randomised controlled trial. Lancet. 1995;346(8974):530–536. doi: 10.1016/S0140-6736(95)91380-7.
    1. Ganguli I, Bassett IV, Dong KL, Walensky RP. Home testing for HIV infection in resource-limited settings. Curr HIV/AIDS Rep. 2009;6(4):217–223. doi: 10.1007/s11904-009-0029-5.
    1. UNAIDS. 2011 UNAIDS World AIDS Day Report. 2011. [ ] Accessed 30 October 2013.
    1. Wachira J, Kimaiyo S, Ndege S, Mamlin J, Braitstein P. What is the impact of home-based HIV counseling and testing on the clinical status of newly enrolled adults in a large HIV care program in Western Kenya? Clin Infect Dis. 2012;54(2):275–281. doi: 10.1093/cid/cir789.
    1. World Health Organization. Planning, Implementation and Monitoring Home-Based HIV Counseling and Testing. A Practical Handbook for Sub-Saharan Africa. 2012. [ ] Accessed 30 October 2013.
    1. British HIV Association. British HIV Association Guidelines for the Treatment of HIV-1-Positive Adults with Antiretroviral Therapy. 2012. [ ] Accessed 30 October 2013.
    1. European AIDS Clinical Society. European AIDS Clinical Society Guidelines. 2013. Accessed 30 October 2013.
    1. Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the Use of Antiretroviral Agents in HIV-1 Infected for Adults and Adolescents. 2011. [ ] Accessed 30 October 2013.
    1. World Health Organization. Antiretroviral Therapy for HIV Infection in Adults and Adolescents. Recommendations for a Public Health Approach (2010 version) 2010. [ ] Accessed 30 October 2013.
    1. HPTN 071 (PopART) Protocol Team. HPTN 071 Population Effects of Antiretroviral Therapy to Reduce HIV Transmission (PopART): A Cluster-Randomized Trial of the Impact of a Combination Prevention Package on Population-Level HIV Incidence in Zambia and South Africa. 2012. [ ] Accessed 30 October 2013.
    1. National AIDS Council Z. Zambia Country Report. Monitoring the Declaration of Commitment on HIV and AIDS and the Universal Access. 2012. [ ] Accessed 30 October 2013.
    1. South African National AIDS Council. Global Aids Response Progress Report 2012, South Africa. 2012. [ ] Accessed 30 October 2013.
    1. Ayles HM, Sismanidis C, Beyers N, Hayes RJ, Godfrey-Faussett P. ZAMSTAR, The Zambia South Africa TB and HIV Reduction Study: design of a 2 x 2 factorial community randomized trial. Trials. 2008;9:63. doi: 10.1186/1745-6215-9-63.
    1. Das M, Chu PL, Santos GM, Scheer S, Vittinghoff E, McFarland W, Colfax GN. Decreases in community viral load are accompanied by reductions in new HIV infections in San Francisco. PLoS One. 2010;5(6):e11068. doi: 10.1371/journal.pone.0011068.
    1. Donnell D, Baeten JM, Kiarie J, Thomas KK, Stevens W, Cohen CR, McIntyre J, Lingappa JR, Celum C. Heterosexual HIV-1 transmission after initiation of antiretroviral therapy: a prospective cohort analysis. Lancet. 2010;375(9731):2092–2098. doi: 10.1016/S0140-6736(10)60705-2.
    1. Obasi A, Mosha F, Quigley M, Sekirassa Z, Gibbs T, Munguti K, Todd J, Grosskurth H, Mayaud P, Changalucha J, Brown D, Mabey D, Hayes R. Antibody to herpes simplex virus type 2 as a marker of sexual risk behavior in rural Tanzania. J Infect Dis. 1999;179(1):16–24. doi: 10.1086/314555.
    1. Cowan FM, Johnson AM, Ashley R, Corey L, Mindel A. Antibody to herpes simplex virus type 2 as serological marker of sexual lifestyle in populations. BMJ. 1994;309(6965):1325–1329. doi: 10.1136/bmj.309.6965.1325.
    1. Nahmias AJ, Lee FK, Beckman-Nahmias S. Sero-epidemiological and -sociological patterns of herpes simplex virus infection in the world. Scand J Infect Dis Suppl. 1990;69:19–36.
    1. Cori A, Ayles H, Beyers N, Schaap A, Floyd S, Sabapathy K, Eaton JW, Hauck K, Smith P, Griffith S, Moore A, Donnell D, Vermund SH, Fidler S, Hayes R, Fraser C. team Hs. HPTN 071 (PopART): A Cluster-Randomized Trial of the population impact of an HIV combination prevention intervention including universal testing and treatment: mathematical model. PLoS One. 2014;9(1):e84511. doi: 10.1371/journal.pone.0084511.
    1. Bennett S, Parpia T, Hayes R, Cousens S. Methods for the analysis of incidence rates in cluster randomized trials. Int J Epidemiol. 2002;31(4):839–846. doi: 10.1093/ije/31.4.839.
    1. Hayes RJ, Alexander ND, Bennett S, Cousens SN. Design and analysis issues in cluster-randomized trials of interventions against infectious diseases. Stat Methods Med Res. 2000;9(2):95–116. doi: 10.1191/096228000670953670.
    1. Hayes RJ, Moulton LH. Cluster Randomised Trials. Boca Raton: Chapman and Hall; 2009.
    1. World Health Organization. Consultation on Antiretroviral Treatment for Prevention of HIV Transmission Meeting report. 2009. [ ] Accessed 30 October 2013.
    1. ANRS 12249 TasP Trial Team. Impact of Immediate Versus WHO Recommendations Guided ART Initiation on HIV Incidence – Feasibility Phase (TasP) [ ] Accessed 30 October 2013.
    1. Botswana Combination Prevention Study Group. Botswana Combination Prevention Project (BCPP) 2012. [ ] Accessed 30 October 2013.
    1. Vermund SH, Hayes RJ. Combination prevention: new hope for stopping the epidemic. Curr HIV/AIDS Rep. 2013;10(2):169–186. doi: 10.1007/s11904-013-0155-y.

Source: PubMed

Sponsorit ja yhteistyökumppanit

Sairaudet

Huumeiden interventiot

3
Tilaa